AXGN Earnings Prediction
The chart below shows how AXGN performed 10 days before and after its earnings report, based on data from the past quarters. Typically, AXGN sees a -3.30% change in stock price 10 days leading up to the earnings, and a +0.47% change 10 days following the report. On the earnings day itself, the stock moves by +7.24%. This data can give you a slight idea of what to expect for the next quarter's release.
AXGN Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
48.64M
17.86%
1.53%
Gross Margin
74.91%
-4.28%
1.55%
Operating Margin
-0.65%
-93.33%
-26.97%
Net Margin
-3.82%
-61.45%
-4.74%
EPS
-0.04
-60.00%
-0.00%
No Data Available
AXGN Earnings Analysis
Axogen, Inc. Common Stock Corporation (AXGN.O) Earnings Conference Call
Positive
Revenue and EBITDA Growth: Revenue was $48.6 million, an increase of approximately 18% compared to last year, while adjusted EBITDA was $6.5 million versus $2.4 million last year.
Positive Revenue and FDA Progress: We are pleased with the positive trends in revenue growth, bottom line performance, and the completion of the rolling submission process and the acceptance by the FDA of the filing of the BLA for Advance Nerve Graft.
Gross Profit Increase: Our gross profit for the quarter was $36.4 million, an increase from the $31.7 million recorded in the third quarter of 2023, representing a gross margin of 74.9%.
Positive Cash Flow Growth: We generated positive cash flow in the third quarter, with a balance of cash, cash equivalents, and investments of $30.5 million compared to $27.1 million at the end of the second quarter of 2024.
2024 Revenue Guidance: We are maintaining our revenue guidance for the fully year 2024 in the range of $182 million to $186 million.
Negative
Revenue Growth Below Expectations: Revenue was $48.6 million, representing a 17.9% growth from the third quarter of 2023, which is below expectations.
Gross Profit Decline: Gross profit for the quarter was $36.4 million, down from $31.7 million recorded in the third quarter of 2023, indicating a decline in gross margin from 76.8% to 74.9%.
Operating Expenses Increase: Total operating expenses for the quarter increased by 2.9% to $36.8 million, up from $35.7 million in Q3 of 2023, indicating rising costs.
R&D Expense Increase: Research and development expenses increased by 4.5% to $7 million from $6.7 million in the third quarter of 2023, reflecting higher investment in R&D without immediate returns.
Net Loss Comparison: The quarter ended with a net loss of $1.9 million or $0.04 per share compared to a net loss of $4.1 million or $0.10 per share in the third quarter of 2023, indicating ongoing financial challenges.
AXGN FAQs
How does AXGN typically perform around its earnings report dates?
Is Axogen, Inc (AXGN) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
AXGN Earning Call Sentiment
Axogen, Inc (AXGN) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
AXGN.O
-0.27%Positive
The earnings call summary reflects strong financial performance with an 18% revenue increase and improved net income. Despite competitive pressures and economic factors, the company raised its revenue guidance, indicating confidence in future growth. The Q&A section confirmed management's strategic focus and positive sentiment towards product innovation and market expansion. While gross margins declined slightly, the overall financial health and cash flow are positive. The absence of a share repurchase program is a minor downside. Overall, the sentiment is positive, with a likelihood of a 2% to 8% stock price increase.